We evaluated the safety and efficacy of long-term lamivudine monotherapy in a group of 25
patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Lamivudine was …

We studied the long‐term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAg‐negative
patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) …

Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is responsible for viral
persistence in the natural course of chronic HBV infection and during prolonged antiviral therapy …

We determined the clinical outcome of hepatitis e antigen (HBeAg)‐negative chronic hepatitis
B patients treated with long‐term nucleos(t)ide analog therapy starting with lamivudine. …

Nucleoside analogues have been recently introduced in the management of chronic hepatitis
B virus (HBV) infection. They mainly act by inhibition of HBV polymerase activity resulting …

We studied the course of virologic breakthroughs detected by a quantitative polymerase
chain reaction (PCR) assay in 32 of 78 patients with hepatitis B e antigen (HBeAg)-negative …

Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus replication. In HBeAg-positive
and HBeAg-negative lamivudine-naïve patients with chronic hepatitis B (CHB), …

Objectives: Oxaliplatin has been introduced in the treatment of advanced colorectal cancer
during the past few years. The pre-existing treatment of leucovorin–5-fluorouracil-irinotecan (…

Objectives: Pegfilgrastim is a new growth factor which can be administered subcutaneously
once (versus multiple doses for days) on the day neutropenia occurs after chemotherapy. …

Background: Adefovir dipivoxil (ADV) is effective in most lamivudine resistant (LAM-R)
chronic hepatitis B (CHB) patients but ADV resistance develops particularly in HBeAg (+) pts. …